.svg)
Most people who start semaglutide experience some side effects, particularly in the early weeks of GLP-1 treatment. The majority of those effects are gastrointestinal, predictable, and manageable. But knowing what to expect, why it happens, and when something warrants medical attention can make the adjustment period a little easier to navigate.
What Are the Most Common Semaglutide Side Effects?
Semaglutide's side-effect profile is well-documented across multiple large clinical trials, including the STEP program for weight management and the SELECT cardiovascular outcomes trial. The effects below reflect data from Wegovy (semaglutide 2.4 mg injection) clinical trials in adults with obesity or overweight unless otherwise noted.
| Side Effect | Approximate Rate (Wegovy 2.4 mg) | Notes |
|---|---|---|
| Nausea | ~44% | Most common; typically peaks early and improves |
| Diarrhea | ~30% | Often front-loaded during dose escalation |
| Vomiting | ~24% | More likely after dose increases |
| Constipation | ~24% | Can persist beyond the initial adjustment period |
| Abdominal pain | ~20% | Includes discomfort, bloating, cramping |
| Headache | ~14% | Often linked to hydration changes |
| Fatigue | ~11% | Usually temporary; most common early |
| Dyspepsia | ~9% | Indigestion and stomach upset |
| Dizziness | ~8% | May relate to hydration or blood pressure changes |
| Acid reflux / heartburn | ~5% | Related to slowed gastric emptying |
| Hair loss | ~3% | Associated with weight loss rather than direct drug effect |
| Dysesthesia | ~2% | Altered skin sensation; increases with higher doses |
The rates above are drawn from placebo-controlled trials and represent the proportion of patients who reported each effect, not the proportion who found it intolerable. Most patients who experienced GI side effects continued treatment. In fact, in clinical trials, only 6.8% of Wegovy-treated adults discontinued due to adverse reactions, with nausea, vomiting, and diarrhea being the most common reasons.
Why Do Semaglutide Side Effects Happen?
Most semaglutide side effects aren't unpredictable reactions: they're direct consequences of how the medication works. Understanding the mechanism helps put those symptoms in context.
Slowed gastric emptying is the primary driver of GI symptoms. Semaglutide activates GLP-1 receptors in the stomach, slowing the movement of food into the small intestine. For a digestive system accustomed to operating at a different pace, the adjustment period can produce nausea, bloating, acid reflux, and burping, particularly in the first weeks of treatment or after dose increases.
Reduced food intake changes gut function. Eating significantly less means less fiber, less water from food, and fewer calories passing through the digestive tract. So, resulting constipation during treatment is often a reflection of these dietary changes as much as the direct effects of the drug.
Dose escalation temporarily intensifies side effects. Semaglutide is titrated upward over 16 weeks to reach the standard maintenance dose. Each dose increase can briefly recreate the adjustment symptoms that occurred at treatment initiation before the body adapts again.
Eating habits amplify or reduce nausea. Semaglutide slows gastric emptying, so eating quickly will load the stomach faster than it can now empty, resulting in nausea. Slowing down at meals is one of the most effective ways patients can lessen the chances for nausea.
Not every symptom is caused by the medication. Separating medication effects from the effects of eating significantly less is not always straightforward. Fatigue, headache, and general unwellness in the early weeks often reflect dehydration, reduced caloric intake, or metabolic adjustment rather than a direct drug reaction.
How Long Do Semaglutide Side Effects Last?
There is no fixed timeline that applies to every patient, but a few patterns emerge consistently across clinical experience.
The first four weeks are typically when GI side effects are most pronounced. Nausea, in particular, tends to peak during this window as the body adjusts to slowed gastric emptying. For most patients, symptoms become meaningfully more manageable before the end of the first month: not necessarily gone, but no longer disruptive.
After each dose increase, expect a temporary return of earlier symptoms. Semaglutide's standard escalation schedule moves through 0.25 mg, 0.5 mg, 1 mg, and 1.7 mg before reaching the 2.4 mg maintenance dose over approximately 16 weeks. Each step can briefly recreate the adjustment period before the body adapts. This is expected and does not indicate that something has gone wrong.
By months two and three, most patients report that GI side effects have settled considerably: either resolving or becoming much more manageable with practical adjustments. Constipation tends to be more persistent than nausea and may require ongoing attention to fiber and hydration throughout treatment.
For a smaller number of patients, side effects remain more disruptive beyond the typical adjustment window. In those cases, dose timing, slower titration, or dietary adjustments can often help. All of these are good reasons to stay in contact with your Lttl care team rather than waiting it out alone or adjusting doses independently.
How to Reduce or Manage Common Side Effects
Most semaglutide side effects respond well to practical adjustments. These are evidence-informed strategies, not workarounds.
For nausea:
Eat smaller meals and slow down while eating. This is the single most effective intervention for most patients. Semaglutide slows how quickly the stomach empties, and eating quickly overloads a stomach that can no longer keep up.
Avoid high-fat, heavily spiced, and fried foods, particularly early in treatment. These independently slow gastric emptying and compound the effect of the medication.
Don't lie down immediately after eating. Staying upright for at least an hour after meals reduces reflux and post-meal nausea.
If your nausea is worse in the morning, try eating something small before getting out of bed.
Some patients find that timing their weekly injection before bed reduces peak nausea effects during waking hours. Discuss timing adjustments with your clinician rather than changing your schedule independently.
For constipation:
Increase dietary fiber intentionally. Reduced food intake often reduces fiber intake. Vegetables, legumes, whole grains, or a fiber supplement can all help minimize constipation.
Prioritize hydration throughout the day. Semaglutide can dampen thirst cues, and reduced food intake decreases water obtained from food. Consistent intake matters more than catching up in large amounts ... so, always keep your water bottle handy!
For acid reflux:
Avoid eating close to bedtime.
Limit carbonated beverages, which worsen reflux when gastric emptying is slowed.
Elevating the head of the bed slightly helps some patients with overnight symptoms.
For fatigue:
Prioritize protein. Eating less without being deliberate about protein quality accelerates muscle loss and compounds fatigue. Aim to eat protein first at each meal before appetite is satisfied by other foods.
Monitor electrolytes. Sodium, potassium, and magnesium drop with reduced food intake and contribute meaningfully to tiredness and headache.
One firm boundary: Do not adjust your semaglutide dose based on side effects without talking to your clinician. Dose timing, rate of escalation, and titration changes can all affect your experience, but those decisions should be made with clinical input ... not independently.
Serious Symptoms and When to Seek Medical Help
Most semaglutide side effects are mild and resolve without intervention. The following, however, require prompt medical attention and should not be managed at home or waited out.
| Symptom | Possible Concern | What to Do |
|---|---|---|
| Severe or persistent abdominal pain, especially radiating to the back | Pancreatitis | Stop medication and seek emergency care immediately |
| Upper right abdominal pain, fever, or jaundice (yellowing of skin or eyes) | Gallbladder disease | Contact your clinician promptly or seek urgent care |
| Signs of a serious allergic reaction: swelling of face, lips, tongue or throat; difficulty breathing; severe rash | Hypersensitivity reaction | Seek emergency care immediately |
| Rapid or irregular heartbeat at rest | Possible cardiac reaction | Contact your clinician or seek urgent care |
| Vision changes in patients with type 2 diabetes | Possible diabetic retinopathy progression | Contact your clinician promptly |
| Symptoms of low blood sugar: shakiness, sweating, confusion, rapid heartbeat | Hypoglycemia, more likely if also taking insulin or sulfonylureas | Treat per your clinician's guidance; seek care if severe |
| Severe or persistent vomiting with inability to keep fluids down | Dehydration and possible kidney injury risk | Contact your clinician; seek urgent care if unable to hydrate |
| Neck lump, hoarseness, difficulty swallowing, or shortness of breath | Possible thyroid tumor | Contact your clinician promptly |
Wegovy (semaglutide) carries a boxed warning (the FDA's most serious warning level) for a potential risk of thyroid C-cell tumors, based on animal studies. The human relevance has not been established, but semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Also, if you are having surgery or another procedure that requires general anesthesia or deep sedation, tell your healthcare and anesthesia teams that you take Wegovy. Wegovy delays stomach emptying, which may increase the risk of stomach contents entering the lungs during a procedure.
Follow the patient information included with your medication and contact your prescribing clinician or care team with any symptom that feels unusual or concerning. If you suspect a serious reaction, don't wait for a scheduled appointment.
Who May Have a Higher Risk of Problems?
Certain patients require additional caution before starting semaglutide. Some medical conditions are formal reasons not to use Wegovy (semaglutide), while others require additional evaluation or monitoring. Wegovy should not be used in people with a personal or family history of medullary thyroid carcinoma, MEN2, or a prior serious allergic reaction to semaglutide or a Wegovy ingredient. Here’s a look at some other potential issues:
Personal or family history of medullary thyroid carcinoma (MTC) or MEN2. These are contraindications; semaglutide should not be used in patients with this history.
History of pancreatitis. Semaglutide has been associated with pancreatitis risk. A prior episode (acute or chronic) requires careful evaluation before treatment can be considered.
Gallbladder disease or history of gallstones. Both rapid weight loss and GLP-1 therapy have been independently associated with increased gallbladder events. The incidence of cholelithiasis in Wegovy-treated adults was 1.6% versus 0.7% in placebo groups in clinical trials.
Gastroparesis or severe gastrointestinal motility disorders. Semaglutide is not recommended in patients with severe gastroparesis, because it further slows gastric emptying.
Patients taking insulin or sulfonylureas. These blood sugar-lowering medications, when combined with semaglutide, increase the risk of hypoglycemia. Dose adjustments to existing diabetes medications may be needed and should be clinician-directed.
Patients taking oral medications with narrow therapeutic windows. Semaglutide delays gastric emptying, which can affect the absorption timing of some oral drugs. A notable example from clinical pharmacology studies: levothyroxine exposure was increased 33% when taken with oral semaglutide tablets. A full medication review before starting is essential.
Patients with significant renal impairment. GI side effects, such as vomiting and diarrhea, increase the risk of dehydration and acute kidney injury. Renal function should be monitored in patients experiencing significant GI adverse reactions.
Pregnancy, planned pregnancy, or breastfeeding. Semaglutide should be discontinued at least two months before a planned pregnancy, given its long half-life of approximately one week. Animal studies have shown fetal harm. The March 2026 Wegovy prescribing label notes that breastfeeding is not recommended during treatment with Wegovy tablets due to the presence of SNAC (the absorption enhancer) in breast milk.
History of diabetic retinopathy. Rapid improvement in blood sugar control has been associated with temporary worsening of retinopathy in some patients with type 2 diabetes. Monitoring for progression is recommended.
None of these factors should be self-assessed as reasons to avoid or proceed with treatment. They require clinical evaluation and, we can’t stress this enough, honest disclosure of relevant history to your care team.
Frequently Asked Questions
Are Semaglutide Side Effects Worse at Higher Doses?
Generally speaking, yes. GI side effects are more frequent at higher doses in clinical trial data. In studies of Wegovy 7.2 mg (a newer higher-dose formulation), nausea was reported in approximately 39% of patients compared to 35% at 2.4 mg and 13% on placebo. Dysesthesia (an altered skin sensation) was significantly more common at 7.2 mg (22%) than at 2.4 mg (6%). The standard titration schedule is designed to minimize side effects by giving the body time to adapt at each dose level before increasing further.
Can Semaglutide Cause Hair Loss?
Hair loss has been reported in approximately 3% of Wegovy-treated patients in clinical trials. The current evidence and FDA labeling suggest it is associated with weight loss rather than a direct drug effect: the same pattern seen with other forms of significant caloric restriction. Adequate protein intake and nutritional support during treatment appear to reduce the likelihood. No patients discontinued treatment due to hair loss in the clinical trials reviewed.
Does Semaglutide Affect Mental Health?
The mental health picture for semaglutide has evolved. The suicidal behavior and ideation warning that previously appeared in Wegovy's prescribing information was removed in January 2026 following an FDA review that did not establish a causal link. Some patients report improved mood during treatment: possibly related to improved metabolic health, reduced food preoccupation, and the psychological benefit of meaningful weight loss. Others notice mood changes, particularly early in treatment. Patients with a history of depression, anxiety, or other mood disorders should disclose that history during intake and stay in contact with their care team if they notice changes during treatment.
What Should I Do If I Miss a Dose of Semaglutide?
For once-weekly Wegovy injection: If your next scheduled Wegovy injection is more than 2 days away, take the missed dose as soon as possible. If your next dose is less than 2 days away, skip the missed dose and return to your regular schedule. If you miss two or more consecutive doses, contact your care team: you may need to re-titrate to reduce GI side effects on restarting. Always follow the instructions included with your specific medication or contact your clinician if you're unsure.
Can I Drink Alcohol While Taking Semaglutide?
Alcohol is not absolutely contraindicated with semaglutide, but a few practical considerations apply. Slowed gastric emptying can make alcohol absorption more unpredictable. Alcohol is also dehydrating, which compounds the hydration challenges already present during semaglutide treatment. If you're also taking blood sugar-lowering medications, alcohol can increase hypoglycemia risk. Moderate consumption is worth discussing with your clinician rather than assuming it's fine or that it's forbidden.
Will Side Effects Return If I Stop and Restart Semaglutide?
Typically, yes. If semaglutide is discontinued and then restarted after a gap, the body goes through an adjustment period similar to the initial one. The prescribing label specifically notes that patients who miss two or more consecutive doses may need to re-initiate and follow the dose escalation schedule to reduce GI adverse reactions on restarting. This is one reason that decisions to pause or stop treatment are better made with your clinician rather than independently.
Bibliography
- Novo Nordisk. (2026). Wegovy (semaglutide) injection and tablets: Full prescribing information (Revised March 2026). U.S. Food and Drug Administration. https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/ee06186f-2aa3-4990-a760-757579d8f77b/spl-doc?hl=wegovy
- Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
- Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., Lingvay, I., Oral, T. K., Michelsen, M. M., Plutzky, J., Tornøe, C. W., & Ryan, D. H. (2023). Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine, 389(24), 2221-2232. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- Drucker, D. J. (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism, 57, 101351. https://pubmed.ncbi.nlm.nih.gov/34626851/
- Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017). Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism, 19(9), 1242-1251. https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.12932
- U.S. Food and Drug Administration. (2025). FDA's concerns with unapproved GLP-1 drugs used for weight loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
.svg)
.svg){kind=icon}
